The genetic-sequencing company increased revenue, but still wound up with a wider loss.
Mixed first-quarter results near the top line led to a wider-than-expected first-quarter loss on the bottom line.
Illumina is investors' best buy in this category.
Have you shied away from investing in the biotech sector? Here are three key reasons why you may want to reconsider that decision.
Which genomic-sequencing leader wins in a head-to-head match-up?
Does a better product mean Pacific Biosciences is finally ready to take on Illumina?
What does Roche’s partnership termination with Pacific Biosciences mean for Illumina shareholders?
Here are three reasons to believe that the genomic-sequencing giant is poised to have a prosperous 2017.
Exact Sciences CEO discusses the company's huge opportunities at the J. P. Morgan Healthcare Conference.
Shares rally in response to a number of exciting announcements that were made at the 2017 J.P. Morgan Healthcare Conference.